Sana Biotechnology Inc vs Super Group (SGHC) Limited Ordinary Shares — how do they compare? Sana Biotechnology Inc trades at $2.8 (market cap $836.71M), while Super Group (SGHC) Limited Ordinary Shares trades at $11.33 (market cap $5.86B). The key difference: Super Group (SGHC) Limited Ordinary Shares is far larger — about 7× Sana Biotechnology Inc's market cap, and Super Group (SGHC) Limited Ordinary Shares pays a 1.73% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and Super Group (SGHC) Limited Ordinary Shares for 1 Days on average.
| SANA | SGHC | |
|---|---|---|
Market Cap | $836.71M | $5.86B |
Volume | 4,507,444 | 1,905,788 |
Sector | Health | Consumer Cyclical |
52-Week High | $5.92 | $15.59 |
52-Week Low | $2.68 | $8.52 |
Typical Hold Time | 23 Days | 1 Days |
Enterprise Value | $749.96M | $5.41B |
Dividend Yield | — | 1.73% |
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →Super Group (SGHC) Limited is a holding company for online sports betting and gaming businesses, operating the Betway sports betting brand and the Spin multi-brand online casino portfolio across markets in Europe, the Americas, and Africa.
Read more on SGHC →